Fred Hutchinson Cancer Center and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mod Pathol. 2023 Dec;36(12):100330. doi: 10.1016/j.modpat.2023.100330. Epub 2023 Sep 15.
The World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues has been the internationally accepted standard for over 20 years. The fifth edition of the WHO Classification (WHO-HEM5) is a multidisciplinary effort by pathologists, clinicians and other specialists that builds upon the revised fourth edition published in 2017. Entities in WHO-HEM5 are organized hierarchically. There are several changes in WHO-HEM5 from the previous edition, including addition of new entities, deletion of some entities and recognition or revision of some subtypes reflecting scientific developments and clinical advances during the past few years. Essential and desirable criteria for each entity are included. Here we introduce WHO-HEM5. Four reviews will follow that emphasize important aspects of the classification.
世界卫生组织（世卫组织）造血和淋巴组织肿瘤分类已经是国际公认的标准 20 多年了。第五版世卫组织分类（世卫组织 - HEM5）是病理学家、临床医生和其他专家的多学科努力的结果，它建立在 2017 年出版的修订版第四版的基础上。世卫组织 - HEM5 中的实体是按层次组织的。与前一版相比，世卫组织 - HEM5 有几个变化，包括增加了新的实体，删除了一些实体，并确认或修订了一些反映过去几年科学发展和临床进展的亚型。每个实体都包含必要和理想的标准。在这里我们介绍世卫组织 - HEM5。随后将有四篇评论强调分类的重要方面。
